FMO5 and cardiac hypertrophy: The mechanisms underlying the suppression of NADPH oxidase activity were not described; however, the inhibition of angiotensin II, a potentiator of NADPH oxidase, by DR has been reported [6] and increases in its levels in cardiac tissue were shown to be involved in cardiac hypertrophy induced by pressure overload [40].